In conclusion, our results suggest that ATL III ameliorated BDL-induced liver fibrosis by inhibiting the PI3K/AKT signaling pathway, as well as regulating the glutamine metabolic pathway in the liver, providing a reference for the clinical treatment of liver fibrosis (Figure 9). Here, AKT1 is linked to Hepatic fibrosis.